<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01707251</url>
  </required_header>
  <id_info>
    <org_study_id>2011_436</org_study_id>
    <nct_id>NCT01707251</nct_id>
  </id_info>
  <brief_title>Intravenous Ibuprofen for Laparoscopic Bariatric Surgery</brief_title>
  <official_title>Intravenous Ibuprofen for Laparoscopic Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jacobi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sagatech Electronics Inc, Alberta, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jacobi Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this study is to test hypothesis that IV ibuprofen decreases 24 hours&#xD;
      morphine requirement using IV PCA in patients after laparoscopic bariatric surgery. Secondary&#xD;
      objective is to determine if it decreases respiratory depression measured using RD, improves&#xD;
      area under curve (AUC) for pain scores at rest (AUCr) and with cough (AUCa) and pressure pain&#xD;
      threshold (PPT) (important for mobilization). Tertiary objective is to compare incidence of&#xD;
      nausea/vomiting, sedation, itching, blood transfusion, over sedation, urinary retention, GI&#xD;
      or surgical bleeding, renal dysfunction, time to clears and baseline activity in ibuprofen&#xD;
      and control groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will recruit patients scheduled for laparoscopic bariatric surgery at Jacobi&#xD;
      Medical Center (100 patients with allowance for 20% drop-offs). Patients will be randomized&#xD;
      to IV Ibuprofen versus placebo to test if morphine usage can be decreased, pain control&#xD;
      improved, pressure pain thresholds increased and respiratory depression decreased.&#xD;
&#xD;
      Exclusion/withdrawal criteria:&#xD;
&#xD;
      Patients with history of ibuprofen or aspirin allergy, morphine allergy, opioid or&#xD;
      psychotropic medication use pre-operatively, patients who would show positive preoperative&#xD;
      U-tox screening, patients unable to sign consent and patients unable to understand or use&#xD;
      patient controlled analgesia (PCA) or report pain intensity will be excluded. Patients with&#xD;
      GFR&lt;60 or history of GI bleed within 6 weeks will be excluded. Patients will be withdrawn&#xD;
      from the study if PCA would have to be discontinued, or the patient would develop acute renal&#xD;
      failure, GI bleed or post-surgical bleed. Intention to treat analysis will be performed&#xD;
      including the dropouts.&#xD;
&#xD;
      Patients' instructions and protocol:&#xD;
&#xD;
      Patients consented for the study will be educated about morphine PCA for pain control and&#xD;
      about pain reporting using NRS-11 and VAS scale at rest and with cough or during incentive&#xD;
      spirometry. They will receive instructions about Remmers Sleep Recorder (SagaTech Calgary,&#xD;
      Alberta, Canada), which includes continuous oximetry, and device will be provided for&#xD;
      overnight home screening preoperatively {Whitelaw,W.A. 2005;}. The sleep recorder data will&#xD;
      be reviewed pre-operatively and patients with respiratory disturbance index (RDI, measured as&#xD;
      oxygen desaturation event) &gt;15/hour who do not have OSA diagnosis and do not use CPAP will be&#xD;
      referred for sleep study and/or CPAP titration before the surgery, Patients will be educated&#xD;
      on QST testing using pressure algometry with 1cm2 padded tip {Coronado 2010} and will be&#xD;
      given survey questionnaire (postoperative diary) for self-reporting of pain (VAS at rest and&#xD;
      with cough), nausea/vomiting, activity and side effects from medications as well as&#xD;
      satisfaction with recovery and pain control. Baseline pressure pain thresholds (N/cm2) will&#xD;
      be tested at abdomen (area of postoperative hyperalgesia) and the pulp of third finger finger&#xD;
      on the right (reference site) using average of three measurements per site.&#xD;
&#xD;
      On the day of surgery patients will be allocated to group A or B according to&#xD;
      randomization.com generated table for two groups with variable blocking factor. Group A and B&#xD;
      assignment to the ibuprofen versus control will be available to the pharmacy only until the&#xD;
      completion of the study and statistical analysis.&#xD;
&#xD;
      The pharmacy will store Ibuprofen and on the day of surgery will provide the covered bag of&#xD;
      ibuprofen 800mg versus saline solution labeled with the patient's name .Group assignment (A&#xD;
      or B) will be known to the pharmacy only. IV will be started and first dose of medication&#xD;
      will be given over 5-30 minutes preoperatively. In the subgroup of patients, where surgery&#xD;
      start time is delayed by one hour or more, PPT will be repeated before the start of the&#xD;
      surgery.&#xD;
&#xD;
      Patients will have standardized general anesthetic for the surgery. Intraoperative opioid&#xD;
      usage will be recorded. Laparoscopic ports will be infiltrated with local anesthetic.&#xD;
&#xD;
      800mg Ibuprofen or placebo infusion will be repeated every 6 hours for 24 hours&#xD;
      postoperatively.&#xD;
&#xD;
      In recovery room patients will be started on morphine patient controlled analgesia (morphine&#xD;
      PCA 0.5mg every 5 minutes while NPO, with ability to escalate the dose up to 1 mg every&#xD;
      5minutes per hospital PCA protocol if patient requires additional morphine rescue to control&#xD;
      the pain, uses PCA appropriately and demonstrates no side effects). Patients will have&#xD;
      antiemetics and morphine loading/rescue dose (4mg Q15minute max 16mg per PACU nurse&#xD;
      discretion) per standard hospital protocol. Patients will be continuously monitored overnight&#xD;
      per nursing protocol and in addition to that with Remmer's unit (pulse oximetry, respiratory&#xD;
      effort, respiratory flow, airway pressure). Pain score at rest and with cough and&#xD;
      nausea/vomiting will be assessed periodically and will be reported by patient in the&#xD;
      postoperative diary. Pain scores will be integrated separately over 24 hours to obtain area&#xD;
      under curve at rest (AUCr) and with cough or activity (AUCa) Overnight oximetry recordings&#xD;
      will be analyzed post hoc to determine RDI. Patients with PCA will be monitored per hospital&#xD;
      policy (Q1h x 12h, then Q2hx 12h). All bariatric patients are continuously monitored&#xD;
      overnight in the PACU or surgical step-down unit. Nurses taking care of the patient routinely&#xD;
      notify anesthesia and/or surgical team about significant apnea/hypopnea.&#xD;
&#xD;
      PCA usage log will be obtained from the pump and morphine given by the nurses will be added&#xD;
      to calculate postoperative morphine cumulative dose for 24 hours. If PCA is discontinued,&#xD;
      patient data will be analyzed as drop-off. Per hospital PCA policy in the event of excessive&#xD;
      sedation and/or respiratory depression (level of sedation 4) following actions are to be&#xD;
      taken:&#xD;
&#xD;
        -  STOP PCA PUMP, stimulate patient, support respirations with bag valve mask as needed&#xD;
&#xD;
        -  Have a coworker notify the Rapid Response Team. Arrange for BMV, O2, and suction.&#xD;
&#xD;
        -  Hang Naloxone 0.8mg in 100ml 0.9% NS IVSS -continue until respirations are more than 9&#xD;
           b/m or a total of 0.8mg is infused.&#xD;
&#xD;
      Time 0 for the purposes of study will be time of admission to PACU. PPT will be tested in the&#xD;
      PACU in the subset of patients who are awake and wiling to perform QST testing, when their&#xD;
      pain is controlled with NRS&lt;=4. QST will be repeated in qualifying patients (awake, pain&#xD;
      controlled) following day.&#xD;
&#xD;
      In addition investigators will record:&#xD;
&#xD;
        1. Transfusion requirement (number of units)&#xD;
&#xD;
        2. Difference between pre-operative and discharge hemoglobin&#xD;
&#xD;
        3. Requirement for surgical revision due to anastomotic leak&#xD;
&#xD;
        4. Incidence of wound infection&#xD;
&#xD;
        5. Readmission rate within 30 days&#xD;
&#xD;
        6. Preoperative and discharge GFR&#xD;
&#xD;
        7. Timed NRS-11 (nurse recorded) and VAS (self reported) for pain at rest and during cough&#xD;
           or incentive spirometry.&#xD;
&#xD;
        8. Area under the curve AUCr using NRS at rest and during incentive spirometry/cough&#xD;
           (AUCa). AUCr and AUCa will be separately integrated to area under curve for 24 hours.&#xD;
&#xD;
        9. Total dose of morphine given by nurses for 24 hours.&#xD;
&#xD;
       10. Morphine PCA usage (hourly and cumulative/24h)&#xD;
&#xD;
       11. Presence of nausea/vomiting for 24 hours&#xD;
&#xD;
       12. Antiemetic requirement (number of doses).&#xD;
&#xD;
       13. Time to oral tolerance (clears, solids) (hours)&#xD;
&#xD;
       14. Time to bowel movement (hours)&#xD;
&#xD;
       15. Time patient meets discharge criteria from the PACU (hours)&#xD;
&#xD;
       16. Time to discharge from PACU (hours)&#xD;
&#xD;
       17. Time to discharge from hospital (hours)&#xD;
&#xD;
       18. Respiratory disturbance index) baseline and postoperatively (from Remmers unit)&#xD;
&#xD;
       19. Incidence of desaturation to SpO2&lt;95, &lt;90 and &lt;80% baseline and postoperatively (from&#xD;
           Remmers unit). Maximum FiO2 required postoperatively (excluding first 2 hours&#xD;
           immediately after surgery).&#xD;
&#xD;
       20. Incidence of over sedation (sedation score 3 and 4)&#xD;
&#xD;
       21. Naloxone requirement if any&#xD;
&#xD;
       22. Patient satisfaction scores&#xD;
&#xD;
       23. Time to out of bed to chair (hours)&#xD;
&#xD;
       24. Time to stand-up (hours)&#xD;
&#xD;
       25. Time to ambulation (hours)&#xD;
&#xD;
       26. Time to baseline physical activity (days)&#xD;
&#xD;
       27. Max temperature&#xD;
&#xD;
       28. Incidence of DVT&#xD;
&#xD;
       29. Reason for delayed discharge (&gt;72 hours)&#xD;
&#xD;
       30. Incidence of readmission within 4 weeks&#xD;
&#xD;
       31. Incidence of reoperation within 4 weeks&#xD;
&#xD;
      Data will be analyzed using commercially available statistical software.&#xD;
&#xD;
      If dropouts to the study will be present, intent to treat analysis will be performed.&#xD;
&#xD;
      Metric scale data will be tested for normality of distribution (Kolmogorov-Smirnov test).&#xD;
      Categorical data will be presented as absolute frequency and relative distribution. For&#xD;
      normally distributed data, a t test for independent samples will be used to compare pre/post&#xD;
      differences between the treatment groups. Otherwise, a nonparametric Mann-Whitney test will&#xD;
      be used. Categorical data will be compared using chi square test or Fisher exact test for&#xD;
      groups &lt;5. Bonferonni correction will be done for multiple comparisons.&#xD;
&#xD;
      After comparing groups for age, sex, BMI, co morbidities, surgical time, baseline pressure&#xD;
      pain thresholds investigators will investigate whether assignment into ibuprofen or saline&#xD;
      groups makes a difference In the primary, secondary and tertiary outcomes.&#xD;
&#xD;
      Our null hypothesis (H0) is that there will be no differences in cumulative 24h morphine&#xD;
      consumption, AUCa and AUCr for pain scores, and that there will be no change in pre/post&#xD;
      difference in RDI and pressure pain thresholds. In addition investigators hypothesize that&#xD;
      there will be no difference in the incidence of nausea/vomiting, discharge readiness, patient&#xD;
      satisfaction among the test and control groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hours postoperative morphine requirement using IV PCA</measure>
    <time_frame>24 hours</time_frame>
    <description>Will test if IV ibuprofen decrease postoperative morphine requirement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory depression</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Compare respiratory disturbance index preoperatively versus postoperatively and incidence of hypoxia (SpO2 &lt;95, &lt;90 and &lt;80%) in ibuprofen and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Area under curve for pain scores at rest (AUCr) and with cough (AUCa).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain thresholds</measure>
    <time_frame>24 hours</time_frame>
    <description>Preoperative versus postoperative pressure pain threshold (PPT) will be measured to assess effect of ibuprofen on PPT (important for mobilization).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nausea/vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Compare incidence of nausea vomiting between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Transfusion requirement</measure>
    <time_frame>3 days</time_frame>
    <description>Compare incidence of blood transfusions between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary retention</measure>
    <time_frame>3 days</time_frame>
    <description>Incidence of recatheterization after foley removal between groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Surgical bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of reoperation for bleeding in ibuprofen and control groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of renal dysfunction</measure>
    <time_frame>3 days</time_frame>
    <description>Compare preoperative versus discharge GFR in ibuprofen and control groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to oral intake</measure>
    <time_frame>3 days</time_frame>
    <description>Time to clears in ibuprofen and control groups.</description>
  </other_outcome>
  <other_outcome>
    <measure>Return of baseline activity</measure>
    <time_frame>30 days</time_frame>
    <description>Time to baseline activity in ibuprofen and control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Time patient meets discharge criteria from the PACU (hours)</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to discharge from PACU (hours)</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to discharge from hospital (hours)</measure>
    <time_frame>1 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to ambulation (hours)</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of readmission within 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of reoperation within 4 weeks</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of DVT</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Max temperature</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to oral tolerance (clears, solids) (hours)</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Antiemetic requirement (number of doses)</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to bowel movement (hours)</measure>
    <time_frame>1 week</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of over sedation (sedation score 3 and 4)</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Naloxone requirement</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction scores</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to out of bed to chair (hours)</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to stand-up (hours)</measure>
    <time_frame>3 days</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Intravenous Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV saline every 6 hours starting preoperatively (5 doses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Ibuprofen</intervention_name>
    <description>800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).</description>
    <arm_group_label>Intravenous Ibuprofen</arm_group_label>
    <other_name>Caldorol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for laparoscopic bariatric surgery at Jacobi Medical Center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with history of ibuprofen or aspirin allergy&#xD;
&#xD;
          -  morphine allergy&#xD;
&#xD;
          -  opioid or psychotropic medication use pre-operatively&#xD;
&#xD;
          -  positive preoperative U-tox screening&#xD;
&#xD;
          -  unable to sign consent and patients unable to understand or use patient controlled&#xD;
             analgesia (PCA) or report pain intensity&#xD;
&#xD;
          -  GFR &lt;60 or history of GI bleed within 6 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mindaugas Pranevicius, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jacobi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2012</study_first_posted>
  <last_update_submitted>September 2, 2015</last_update_submitted>
  <last_update_submitted_qc>September 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jacobi Medical Center</investigator_affiliation>
    <investigator_full_name>Mindaugas Pranevicius</investigator_full_name>
    <investigator_title>Attending Anesthesiologist, Director of Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>Obesity, Morbid</keyword>
  <keyword>Bariatric Surgery</keyword>
  <keyword>Laparoscopy</keyword>
  <keyword>Intravenous Ibuprofen</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Morphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

